Share
array:24 [ "pii" => "S238702062030406X" "issn" => "23870206" "doi" => "10.1016/j.medcle.2019.12.007" "estado" => "S300" "fechaPublicacion" => "2020-10-09" "aid" => "5072" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2020" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Med Clin. 2020;155:316-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0025775320300889" "issn" => "00257753" "doi" => "10.1016/j.medcli.2019.12.009" "estado" => "S300" "fechaPublicacion" => "2020-10-09" "aid" => "5072" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Med Clin. 2020;155:316-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta científica</span>" "titulo" => "Colesterol LDL en un paso" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "316" "paginaFinal" => "317" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "LDL cholesterol in one step" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1383 "Ancho" => 2917 "Tamanyo" => 163166 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Algoritmo terapéutico para alcanzar el objetivo en colesterol LDL en un solo paso.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Nota: no se incluyen los inhibidores de PCSK9 al estar solo indicados según el informe de posicionamiento terapéutico en casos de prevención secundaria y/o hipercolesterolemia familiar que no alcanzan el objetivo terapéutico a pesar de estar tratados con la dosis máxima de la estatina tolerada o ser intolerantes a las estatinas.</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">cLDL: colesterol ligado a <span class="elsevierStyleItalic">low density lipoproteins</span> («lipoproteínas de baja densidad»); EZE: ezetimiba; RCV: riesgo cardiovascular; Tto: tratamiento.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juan Pedro-Botet, Elisenda Climent" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Juan" "apellidos" => "Pedro-Botet" ] 1 => array:2 [ "nombre" => "Elisenda" "apellidos" => "Climent" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S238702062030406X" "doi" => "10.1016/j.medcle.2019.12.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S238702062030406X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775320300889?idApp=UINPBA00004N" "url" => "/00257753/0000015500000007/v1_202009230624/S0025775320300889/v1_202009230624/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2387020620304253" "issn" => "23870206" "doi" => "10.1016/j.medcle.2020.06.011" "estado" => "S300" "fechaPublicacion" => "2020-10-09" "aid" => "5279" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2020;155:318-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Expanded mesenchymal stem cells: a novel therapeutic approach for SARS-CoV-2 pneumonia (COVID-19). Concepts regarding a first case in Spain" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "318" "paginaFinal" => "319" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Abordaje terapéutico del SARS-CoV-2 (COVID-19) mediante células mesenquimales de médula ósea alogénica expandidas. Conceptos a propósito de un primer caso en España" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1482 "Ancho" => 2917 "Tamanyo" => 580478 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Coronal sequence at two levels of the chest CT scan before and after stem-cell therapy, showing normal conditions one month after cell therapy.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Robert Soler Rich, Joan Rius Tarruella, María Teresa Melgosa Camarero" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Robert" "apellidos" => "Soler Rich" ] 1 => array:2 [ "nombre" => "Joan" "apellidos" => "Rius Tarruella" ] 2 => array:2 [ "nombre" => "María Teresa" "apellidos" => "Melgosa Camarero" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775320304073" "doi" => "10.1016/j.medcli.2020.06.018" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775320304073?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020620304253?idApp=UINPBA00004N" "url" => "/23870206/0000015500000007/v1_202010060722/S2387020620304253/v1_202010060722/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2387020620304095" "issn" => "23870206" "doi" => "10.1016/j.medcle.2019.05.038" "estado" => "S300" "fechaPublicacion" => "2020-10-09" "aid" => "4919" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Med Clin. 2020;155:315-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Viral etiology of exacerbations of patients with chronic obstructive pulmonary disease during the winter season" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "315" "paginaFinal" => "316" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Etiología viral de las exacerbaciones de los pacientes con enfermedad pulmonar obstructiva crónica en la época invernal" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jordi Reina, Ernest Sala, Pablo Fraile" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Jordi" "apellidos" => "Reina" ] 1 => array:2 [ "nombre" => "Ernest" "apellidos" => "Sala" ] 2 => array:2 [ "nombre" => "Pablo" "apellidos" => "Fraile" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775319304403" "doi" => "10.1016/j.medcli.2019.05.025" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775319304403?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020620304095?idApp=UINPBA00004N" "url" => "/23870206/0000015500000007/v1_202010060722/S2387020620304095/v1_202010060722/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "LDL cholesterol in one step" "tieneTextoCompleto" => true "saludo" => "Dear Editor:" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "316" "paginaFinal" => "317" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Juan Pedro-Botet, Elisenda Climent" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Juan" "apellidos" => "Pedro-Botet" "email" => array:1 [ 0 => "86620@parcdesalutmar.cat" ] "referencia" => array:4 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 3 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Elisenda" "apellidos" => "Climent" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Servicio de Endocrinología y Nutrición, Hospital del Mar, Barcelona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Departament de Medicina, Universitat Autònoma de Barcelona, Campus Universitari Mar, Barcelona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Colesterol LDL en un paso" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1383 "Ancho" => 2917 "Tamanyo" => 157491 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Therapeutic algorithm to reach the LDL cholesterol goal in one step.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Note: PCSK9 inhibitors are not included as they are only indicated according to the therapeutic positioning report in cases of secondary prevention and/or familial hypercholesterolemia that do not reach the therapeutic objective despite being treated with the maximum tolerated statin dose or being intolerant to statins.</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">LDL-C: cholesterol linked to <span class="elsevierStyleItalic">low density lipoproteins</span>; EZE: ezetimibe; CVR: cardiovascular risk; Rx: treatment, therapy.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">In line with the joint recommendation of the <span class="elsevierStyleItalic">European Society of Cardiology</span> and the <span class="elsevierStyleItalic">European Atherosclerosis Society</span> of 2016 on the control of dyslipidemia<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a>, the 2019 guidelines provide additional data from observational, randomized-clinical, and genetic Mendelian randomization studies that unequivocally show the causal effect of <span class="elsevierStyleItalic">low density lipoproteins</span> (LDL) cholesterol in the development of cardiovascular disease of atherosclerotic origin. The therapeutic objectives of the current guidelines point to the concentration of LDL cholesterol as the main therapeutic target and has incorporated a higher level of demand based on new clinical evidence. In this sense, the recommended therapeutic target for very high-risk subjects based on the results of the IMPROVE-IT<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a>, FOURIER<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> and ODISSEY<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> studies is LDL cholesterol <55<span class="elsevierStyleHsp" style=""></span>mg/dl and a reduction ≥50% with respect to baseline LDL. Furthermore, this evidence points to switching high-potency statins to high-intensity lipid-lowering therapies. In the therapeutic algorithm for the pharmacological reduction of LDL cholesterol, the guidelines recommend using the statin with the necessary potency to achieve the required reduction based on the target LDL cholesterol, then go to the maximum tolerated dose if the objective is not achieved, then add ezetimibe and, if the goal is still not achieved, add a PCSK9 inhibitor.</p><p id="par0010" class="elsevierStylePara elsevierViewall">All of this implies that in the case of a very high-risk patient with baseline LDL cholesterol >140<span class="elsevierStyleHsp" style=""></span>mg/dl, it will require the use of triple lipid-lowering therapy and, therefore, the therapeutic objective will not be achieved before 6 months. We know that the main obstacle in clinical practice is still the lack of achievement of therapeutic targets for LDL cholesterol, as a result of under-treatment. Prior treatment planning using the updated tables of Masana and Plana<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a>, or the use of computerized tools incorporated into the clinical history have demonstrated a significant improvement in the rate of therapeutic objective achievement. Given the importance of “the lower the better” LDL cholesterol, but also “the sooner the better” according to the results of the Mendelian randomization studies, we consider it appropriate to follow the algorithm proposed in <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a> in order to reach the LDL cholesterol goal in one step and, in this way, achieve an effective cardiovascular prevention.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflict of interests</span><p id="par0015" class="elsevierStylePara elsevierViewall">Juan Pedro-Botet reports having received consulting fees from Amgen, Mylan and Sanofi, and conference fees from Amgen, AstraZeneca, Esteve, Ferrer, MSD, Mylan, Sanofi, activities not related to this study.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Elisenda Climent declares that she has no conflict of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflict of interests" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Pedro-Botet J, Climent E. Colesterol LDL en un paso. Med Clín. 2020;155:316–317.</p>" ] ] "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1383 "Ancho" => 2917 "Tamanyo" => 157491 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Therapeutic algorithm to reach the LDL cholesterol goal in one step.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Note: PCSK9 inhibitors are not included as they are only indicated according to the therapeutic positioning report in cases of secondary prevention and/or familial hypercholesterolemia that do not reach the therapeutic objective despite being treated with the maximum tolerated statin dose or being intolerant to statins.</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">LDL-C: cholesterol linked to <span class="elsevierStyleItalic">low density lipoproteins</span>; EZE: ezetimibe; CVR: cardiovascular risk; Rx: treatment, therapy.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2016 ESC/EAS guidelines for the management of dyslipidaemias" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "ESC Scientific Document Group" "etal" => true "autores" => array:6 [ 0 => "A.L. Catapano" 1 => "I. Graham" 2 => "G. de Backer" 3 => "O. Wiklund" 4 => "M.J. Chapman" 5 => "H. Drexel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehw272" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2016" "volumen" => "37" "paginaInicial" => "2999" "paginaFinal" => "3058" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27567407" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ezetimibe added to statin therapy after acute coronary syndromes" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "IMPROVE-IT Investigators" "etal" => true "autores" => array:6 [ 0 => "C.P. Cannon" 1 => "M.A. Blazing" 2 => "R.P. Giugliano" 3 => "A. McCagg" 4 => "J.A. White" 5 => "P. Theroux" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1410489" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2015" "volumen" => "372" "paginaInicial" => "2387" "paginaFinal" => "2397" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26039521" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evolocumab and clinical outcomes in patients with cardiovascular disease" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "FOURIER Steering Committee and Investigators" "etal" => true "autores" => array:6 [ 0 => "M.S. Sabatine" 1 => "R.P. Giugliano" 2 => "A.C. Keech" 3 => "N. Honarpour" 4 => "S.D. Wiviott" 5 => "S.A. Murphy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1615664" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2017" "volumen" => "376" "paginaInicial" => "1713" "paginaFinal" => "1722" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28304224" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Alirocumab and cardiovascular outcomes after acute coronary syndrome" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "ODYSSEY OUTCOMES Committees and Investigators" "etal" => true "autores" => array:6 [ 0 => "G.G. Schwartz" 1 => "P.G. Steg" 2 => "M. Szarek" 3 => "D.L. Bhatt" 4 => "V.A. Bittner" 5 => "R. Diaz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1801174" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2018" "volumen" => "379" "paginaInicial" => "2097" "paginaFinal" => "2107" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30403574" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update of therapeutic planning tables oriented towards obtaining therapeutic objectives" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L. Masana" 1 => "N. Plana" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arteri.2019.04.005" "Revista" => array:6 [ "tituloSerie" => "Clin Investig Arterioscler" "fecha" => "2019" "volumen" => "31" "paginaInicial" => "271" "paginaFinal" => "277" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31296342" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23870206/0000015500000007/v1_202010060722/S238702062030406X/v1_202010060722/en/main.assets" "Apartado" => array:4 [ "identificador" => "43311" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Scientific letters" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23870206/0000015500000007/v1_202010060722/S238702062030406X/v1_202010060722/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S238702062030406X?idApp=UINPBA00004N" ]
